The use of oligonucleotides to target RNA for therapeutic efforts and research studies has gained popularity, with RNAi and Antisense Oligonucleotide (ASO) approaches being used extensively in clinical trials, culminating in the first ever RNAi therapeutic being approved by the FDA in 2018. RNA therapeutics present a powerful, precise tool for targeting previously untreatable diseases, and for this reason patents protecting these therapeutics are extremely valuable.
Our team has extensive experience in this area, both professionally in the legal sphere and through our scientific training. A number of our team have biochemical backgrounds, which means we can fully engage with inventors and clients to understand their R&D and specific legal needs.
This has led to us being selected to handle various RNA therapeutic patent portfolios, which have involved leading FTO strategies and complex prosecutions and oppositions before the EPO. Most recently our team ran a multi-jurisdictional litigation for Silence against Alnylam, including obtaining granted patents for Silence and then successfully defending them against multiple oppositions.
